Alzheimer's 8: Aducanumab for Treatment of Alzheimer's Disease - Controversy and Appropriate Communications
Description
Panel discussion among neurologists and geriatric psychiatrists to clarify controversial issues surrounding the FDA’s recent approval of Aducanumab for treatment of Alzheimer's disease, and appropriate messaging to patients and family members. Following their presentations, the panel experts will conduct a question-and-answer session.
| Course ID #: | TJE 210948.0 | Issue Date: | 8/23/2021 | Expiration Date: | 8/23/2023 |
Objectives
After completing this activity, learners will be able to:
- Evaluate the issues surrounding Aducanumab's FDA approval; results of clinical trials, and future trials.
- Assess patients for appropriateness when using this drug.
- Create a plan to promote effective communications with patients at various stages of Alzheimer's disease and their family members.
Disclosure
No individual in a position to control or influence the content of this activity has reported relevant financial relationships with commercial interests. No commercial support was provided for this activity.
Disclaimer
The information and guidelines contained in this activity are generalized and may not apply to all practice situations. We recommend that legal advice be obtained from a qualified attorney for specific application to your practice. The information is intended for educational purposes and should be used as a reference guide only.
Course Developers
Steve Koh, MD, MPH, MBA, Geriatric Psychiatrist, UC San Diego Health
Michael Lobatz, MD, Neurologist, The Neurology Center and Scripps Center
Douglas Galasko, MD, Neurologist, UC San Diego Health
Gregory Sahagian, MD. Neurologist, The Neurology Center and Scripps Health
Ian Neel, MD, Geriatrician, UC San Diego Health
Liz Spier, MD, Neurologist, Southern California Permanente Medical Group
Barbara Mandel, MBA, Alzheimer's Project Facilitator, Champions for Health
Johanna Lackner, MPH, MSW, Senior Director, Continuing Professional Development, Department of Patient Safety and Risk Management, The Doctors Company
Continuing Education Credit
The Doctors Company is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical educational activities for physicians.
The Doctors Company designates this activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Joint Providership
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Doctors Company and Champions for Health. The Doctors Company is accredited by the ACCME to provide continuing medical education for physicians.
Complies with State Requirements
Please SEE the Federation of State Medical Boards overview of Continuing Medical Education requirements by State.
Technical Requirements
The activity is best experienced using the most current browser: Firefox, Chrome, Safari, or Microsoft Edge. Internet Explorer is not supported on this platform. All activities featuring audio must have a speaker. To view graphic images and references that appear in separate "pop-up" windows, JavaScript and session cookies must be enabled on your computer. Adobe Acrobat Reader may be required for certain activities.
Contact Us
If you have questions, contact educationsupport@thedoctors.com or call 800.421.2368.
Resource
Download The Alzheimer's Project Clinical Roundtable (Champions for Health) PPT Presentation: Resource